CN-105
Phase 2UNKNOWN 1 views this week 0 watching💤 Quiet
Interest: 28/100
28
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Intracerebral Hemorrhage
Conditions
Intracerebral Hemorrhage
Trial Timeline
Aug 24, 2022 → Aug 1, 2024
NCT ID
NCT06255977About CN-105
CN-105 is a phase 2 stage product being developed by Tiantan Bio for Intracerebral Hemorrhage. The current trial status is unknown. This product is registered under clinical trial identifier NCT06255977. Target conditions include Intracerebral Hemorrhage.
What happened to similar drugs?
0 of 2 similar drugs in Intracerebral Hemorrhage were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
12
Activity
4
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06255977 | Phase 2 | UNKNOWN |
Competing Products
6 competing products in Intracerebral Hemorrhage
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Edaravone Dexborneol + Placebo | Sun Pharmaceutical | Phase 2 | 31 |
| NXY-059 | AstraZeneca | Phase 2 | 35 |
| Recombinant Factor VIIa + Biological/Vaccine: Placebo | Novo Nordisk | Phase 3 | 47 |
| Recombinant Activated Factor VII (rFVIIa) + Placebo | Novo Nordisk | Phase 3 | 44 |
| PF-05230907 | Pfizer | Phase 1 | 21 |
| Albumin + Placebo | Baxter | Phase 2 | 24 |